{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:26:45Z","timestamp":1792567605283,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01232-w","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T08:01:06Z","timestamp":1739865666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-5822","authenticated-orcid":false,"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-4485","authenticated-orcid":false,"given":"Horatiu","family":"Olteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4909-6157","authenticated-orcid":false,"given":"Pedro","family":"Horna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Otteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-1954","authenticated-orcid":false,"given":"Abiola Bukunmi","family":"Bolarinwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Lisa","family":"Hwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"1232_CR1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3390\/cancers13061285","volume":"13","author":"A Schavgoulidze","year":"2021","unstructured":"Schavgoulidze A, Cazaubiel T, Perrot A, Avet-Loiseau H, Corre J. Multiple myeloma: heterogeneous in every way. Cancers. 2021;13:1285.","journal-title":"Cancers"},{"key":"1232_CR2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"1232_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2022","unstructured":"Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36:801\u20138.","journal-title":"Leukemia"},{"key":"1232_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos M-V, et al. Multiple myeloma. Nat Rev Dis Prim. 2017;3:17046.","journal-title":"Nat Rev Dis Prim"},{"key":"1232_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01120-9","volume":"14","author":"NS Joseph","year":"2024","unstructured":"Joseph NS, Kaufman JL, Gupta VA, Hofmeister CC, Dhodapkar MV, Boise LH, et al. Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients. Blood Cancer J. 2024;14:159.","journal-title":"Blood Cancer J"},{"key":"1232_CR6","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/bloodadvances.2023009681","volume":"7","author":"C Charalampous","year":"2023","unstructured":"Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, et al. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Blood Adv. 2023;7:4371\u201380.","journal-title":"Blood Adv"},{"key":"1232_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433520","volume":"44","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, D\u2019Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F. Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies. Am Soc Clin Oncol Educ Book. 2024;44:e433520.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1232_CR8","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1200\/JCO.18.00776","volume":"37","author":"A Perrot","year":"2019","unstructured":"Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019;37:1657\u201365.","journal-title":"J Clin Oncol"},{"key":"1232_CR9","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","volume":"4","author":"N Abdallah","year":"2020","unstructured":"Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4:3509\u201319.","journal-title":"Blood Adv"},{"key":"1232_CR10","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"1232_CR11","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"1232_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00611-x","volume":"12","author":"NH Abdallah","year":"2022","unstructured":"Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12:21.","journal-title":"Blood Cancer J"},{"key":"1232_CR13","unstructured":"Corre J. New IMS Consensus Definition for High Risk Multiple Myeloma. International Myeloma Society; 2024; Rio de Janerio; 2024. S1-S326."},{"key":"1232_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41375-021-01433-9","volume":"36","author":"S Zanwar","year":"2022","unstructured":"Zanwar S, Ho M, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, et al. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia. 2022;36:873\u20136.","journal-title":"Leukemia"},{"key":"1232_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00576-3","volume":"12","author":"CY Soekojo","year":"2022","unstructured":"Soekojo CY, Chung T-H, Furqan MS, Chng WJ. Genomic characterization of functional high-risk multiple myeloma patients. Blood Cancer J. 2022;12:24.","journal-title":"Blood Cancer J"},{"key":"1232_CR16","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27023","volume":"98","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, et al. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023;98:1540\u20139.","journal-title":"Am J Hematol"},{"key":"1232_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.clml.2017.06.020","volume":"17","author":"EH van Beers","year":"2017","unstructured":"van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, et al. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017;17:555\u201362.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1232_CR18","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020\u20138.","journal-title":"Blood"},{"key":"1232_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/bjh.19623","volume":"205","author":"MF Kaiser","year":"2024","unstructured":"Kaiser MF, Pratt G, Bygrave C, Bowles K, Stern S, Jenner M. Diagnosis and initial treatment of transplant-eligible high risk myeloma patients: a British Society for Haematology\/UK Myeloma Society Good Practice Paper. Br J Haematol. 2024;205:833\u2013839.","journal-title":"Br J Haematol"},{"key":"1232_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ajh.20125","volume":"77","author":"S Kumar","year":"2004","unstructured":"Kumar S, Rajkumar SV, Greipp PR, Witzig TE. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments. Am J Hematol. 2004;77:7\u201311.","journal-title":"Am J Hematol"},{"key":"1232_CR21","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1182\/bloodadvances.2019001275","volume":"4","author":"PW Mellors","year":"2020","unstructured":"Mellors PW, Binder M, Ketterling RP, Greipp PT, Baughn LB, Peterson JF, et al. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020;4:2236\u201344.","journal-title":"Blood Adv"},{"key":"1232_CR22","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1182\/bloodadvances.2018024794","volume":"2","author":"MA Aljama","year":"2018","unstructured":"Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, et al. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv. 2018;2:3149\u201354.","journal-title":"Blood Adv"},{"key":"1232_CR23","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","volume":"23","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333\u20138.","journal-title":"J Clin Oncol"},{"key":"1232_CR24","first-page":"25","volume":"113","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, Kumar S. Plasma cell labeling index. Methods Mol Med. 2005;113:25\u201335.","journal-title":"Methods Mol Med"},{"key":"1232_CR25","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1182\/blood.V97.8.2522","volume":"97","author":"DP Steensma","year":"2001","unstructured":"Steensma DP, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA, et al. A high bone marrow plasma cell labeling index in stable plateau\u2013phase multiple myeloma is a marker for early disease progression and death: Presented in abstract form at the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, May 20-23, 2000. Blood. 2001;97:2522\u20133.","journal-title":"Blood"},{"key":"1232_CR26","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/leu.2017.331","volume":"32","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, et al. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia. 2018;32:986\u201395.","journal-title":"Leukemia"},{"key":"1232_CR27","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","volume":"26","author":"M D\u2019Agostino","year":"2020","unstructured":"D\u2019Agostino M, Zaccaria GM, Ziccheddu B, Rustad EH, Genuardi E, Capra A, et al. Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing. Clin Cancer Res. 2020;26:4832\u201341.","journal-title":"Clin Cancer Res"},{"key":"1232_CR28","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/leu.2016.147","volume":"30","author":"N Majithia","year":"2016","unstructured":"Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016;30:2208\u201313.","journal-title":"Leukemia"},{"key":"1232_CR29","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1016\/j.clml.2023.11.006","volume":"24","author":"R Gupta","year":"2024","unstructured":"Gupta R, Jevremovic D, Mathew SJ, Kumar S. Multiparametric flow cytometry in the evaluation of plasma cell proliferative disorders: current paradigms for clinical practice. Clin Lymphoma Myeloma Leuk. 2024;24:e88\u2013e95.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1232_CR30","doi-asserted-by":"crossref","unstructured":"Zanwar S, Kumar S. Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future. Leuk Lymphoma. 2024:1-11.","DOI":"10.1080\/10428194.2024.2443550"},{"key":"1232_CR31","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1016\/j.ajpath.2012.07.020","volume":"181","author":"B Paiva","year":"2012","unstructured":"Paiva B, V\u00eddriales MB, Montalb\u00e1n M, P\u00e9rez JJ, Guti\u00e9rrez NC, Rosi\u00f1ol L, et al. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials. Am J Pathol. 2012;181:1870\u20138.","journal-title":"Am J Pathol"},{"key":"1232_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2010.030296","volume":"96","author":"D Hose","year":"2011","unstructured":"Hose D, R\u00e8me T, Hielscher T, Moreaux J, Messner T, Seckinger A, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2011;96:87\u201395.","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01232-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01232-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01232-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T08:01:10Z","timestamp":1739865670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01232-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01232-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report to conflicts of interest pertaining to the submitted work. PK: Loxo Pharmaceuticals: Research Funding; Kite: Membership on an entity\u2019s Board of Directors or advisory committees; Oncopeptides: Membership on an entity\u2019s Board of Directors or advisory committees; CVS Caremark: Consultancy; Karyopharm: Research Funding; GlaxoSmithKline: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Pharmacyclics: Membership on an entity\u2019s Board of Directors or advisory committees; AbbVie: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity\u2019s Board of Directors or advisory committees; Mustang Bio: Membership on an entity\u2019s Board of Directors or advisory committees; Sanofi: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; BeiGene: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Ichnos: Research Funding; Angitia Bio: Membership on an entity\u2019s Board of Directors or advisory committees; X4 Pharmaceuticals: Membership on an entity\u2019s Board of Directors or advisory committees; Keosys: Consultancy; Bristol Myers Squibb: Research Funding; Regeneron: Research Funding; Amgen: Research Funding. Cook: Geron Corp: Other: Held $600 Geron Stock for one week and sold without profit. AD: Janssen: Research Funding; Alexion: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; HaemaloiX: Research Funding; Alnylam: Research Funding; BMS: Consultancy, Research Funding; Pfizer: Research Funding. DD: Genentech: Consultancy; Sorrento: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; K36 Therapeutics: ResearchFunding; BMS: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Apellis: Consultancy, Honoraria, ResearchFunding; Alexion: Consultancy, Honoraria. TK: Novartis: Research Funding; Pfizer: Research Funding. NL: Checkpoint Therapeutics: Current holder of stock options in a privately held company; AbbVie: Current holder of stock options in a privately held company. Lin: Pfizer: Membership on an entity\u2019s Board of Directors or advisory committees; Janssen: Consultancy, Research Funding; Caribou: Membership on an entity\u2019s Board of Directors or advisory committees; Bristol-Myers Squibb: Consultancy, Research Funding; Sanofi: Consultancy; NexImmune: Membership on an entity\u2019s Board of Directors or advisory committees; Genentech: Consultancy; Legend: Consultancy; Celgene: Consultancy, Research Funding; Regeneron: Consultancy. EM: Protego: Consultancy. YLH: GSK: Honoraria; MultiMedia Medical, LLC: Consultancy; Shield Therapeutics: Honoraria; Janssen: Honoraria; Pfizer: Other: Consulting fee located to Mayo Research fund. SK: Celgene: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Roche: Research Funding; Merck: Research Funding; Takeda: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; KITE: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; MedImmune\/AstraZeneca: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Adaptive: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Oncopeptides: Other: Independent review committee participation; Abbvie: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Sanofi: Research Funding. Rest of the authors do not have any relevant disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}